Rett syndrome is a progressive, neuro-developmental disorder that affects approximately 1 in 10,000 females. Classic Rett syndrome is diagnosed based on a defined set of clinical criteria and characterized by apparently normal development in the first 6-18 months, followed by an arrest in development and subsequent regression in language and motor skills. Frequent symptoms include […]
Rett syndrome is a progressive, neuro-developmental disorder that affects approximately 1 in 10,000 females. Classic Rett syndrome is diagnosed based on a defined set of clinical criteria and characterized by apparently normal development in the first 6-18 months, followed by an arrest in development and subsequent regression in language and motor skills. Frequent symptoms include loss of speech and purposeful hand use, stereotypic hand movements, ataxia, microcephaly, and seizures. “Atypical” Rett syndrome can be milder or more severe than typical Rett syndrome and is diagnosed when some but not all clinical criteria for Rett syndrome are present. The milder form may include mental retardation, mild learning disablilities and/or autism. Mutations in the MECP2 gene have been found to cause Rett syndrome and “atypical” Rett syndrome in females. In males, MECP2 mutations are not as common and responsible for a broad spectrum of neurodevelopmental phenotypes, ranging from severe neonatal encephalopathy to a variety of neuropsychiatric features or mild mental retardation. Rarely, males with a progressive neurodevelopmental syndrome, including mental retardation, spasticity, speech and social problems, have been found to have a duplication or triplication of the MECP2 gene.
CDKL5 mutations have been associated with X-linked mental retardation and a broad spectrum of neurological symptoms that show broad overlap with atypical Rett syndrome and Angelman syndrome. The majority of patients are females. Most patients have a severe phenotype with early-onset encephalopathy and infantile spasms, global developmental delay and mental retardation, although cases with much milder symptoms have been reported.
- STAT Epilepsy Panel
- Rett/Angelman Syndrome Panel
- Comprehensive Epilepsy Panel
- Infantile Epilepsy Panel
- MECP2 Gene Sequencing & Del/Dup
- Childhood-Onset Epilepsy Panel
- CDKL5 Gene Sequencing
- MECP2 Gene Sequencing
- CDKL5 Del/Dup
- MECP2 Del/Dup
- Whole Genome Array (GenomeDx)
STAT Epilepsy Panel
FORMS AND DOCUMENTS
- ALDH7A1, ARX, CDKL5, FOLR1, KCNQ2, KCNQ3, MECP2, MEF2C, PCDH19, PNPO, POLG, SCN1A, SCN1B, SCN2A, SCN8A, SLC2A1, SPTAN1, STXBP1
- Clinical Utility:
- Molecular confirmation of a clinical diagnosis
- To assist with decisions about treatment and management of individuals with epilepsy
- Testing of at-risk relatives for specific known mutation(s) previously identified in an affected family member
- Prenatal diagnosis for known familial mutation(s) in at-risk pregnancies
- Lab Method:
- Exon Array CGH, Next-gen Sequencing
- Test Code:
- Turnaround Time:
- 2 weeks
- Preferred Specimen:
- 2-5 mL Blood - Lavender Top Tube
- CPT Codes:
- 81405x2, 81406x3, 81407x1
- New York Approved:
- ABN Required:
- Billing Information:
- View Neurology Billing Policy
- Ottman et al., (2010) Epilepsia 51:655-670.
- Pong et al., (2011) Pediatr Neurol 44:317-327.
- Nicita et al., (2011) Seizure: Eur J Epilepsy doi:10.1016/j.seizure.2011.08.007
- Zucca et al., (2008) Arch Neurol 65:489-494.
- Harkin et al., (2007) Brain 130:843-852.
- Higurashi et al., (2011) Epilepsy Res dio:10.1016/j.eplepsyres.2011.10.014.
- Depienne et al., (2009) Plos Genet 5(2):e1000381.
- Marini et al., (2010) Neurology 75:646-653.
- Hynes et al., (2010) J Med Genet 47:211-216.
- Depienne et al., (2010) Hum Mutat 32:E1959-E1975.
- Weckhuysen et al., (2012) Ann Neurol 71:15-25.
- Carvill et al., (2014) Neurol 82:1245-1253.
- Mills et al., (2010) Brain 133:2148-2159.
- Nguyen et al., (2006) J Hepatol 45:108-116.
- Isohanni et al., (2011) Neurol 76:811-815.
- Hunter et al., (2011) Pediatr Neurol 45:311-318.
- Kamiya et al., (2004) J Neurosci 24(11):2690-2698.
- Ogiwara et al., (2009) Clin Genet 73(13):1046-1053.
- Veeramah et al., (2012) Am J Hum Genet 90:502-510.
- Saitsu et al., (2010) Am J Hum Genet 886:881-891.
- Gospe et al., (2010) Chang Gung Med 33:1-12.
- Li et al., (2006) J Hum Genet 52:38-47.
- Tao et al., (2004) Am J Hum Genet 75:1149-1154.
- Rosas-Vargas et al., (2008) J Med Genet 45:172-178.
- Zweier et al., (2010) Hum Mutat 31:722-733.
- Grapp et al., (2012) Brain 135:2022-2031.